222 related articles for article (PubMed ID: 15622921)
21. Vaccination strategies in follicular lymphoma.
Kannan S; Neelapu SS
Curr Hematol Malig Rep; 2009 Oct; 4(4):189-95. PubMed ID: 20425407
[TBL] [Abstract][Full Text] [Related]
22. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008.
Fournier P; Schirrmacher V
Expert Rev Vaccines; 2009 Jan; 8(1):51-66. PubMed ID: 19093773
[TBL] [Abstract][Full Text] [Related]
23. Idiotype vaccination strategies in myeloma: how to overcome a dysfunctional immune system.
Rhee Fv
Clin Cancer Res; 2007 Mar; 13(5):1353-5. PubMed ID: 17332275
[No Abstract] [Full Text] [Related]
24. Variations in "rescuability" of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development.
Rodríguez-Calvillo M; Inogés S; López-Díaz de Cerio A; Zabalegui N; Villanueva H; Bendandi M
Crit Rev Oncol Hematol; 2004 Oct; 52(1):1-7. PubMed ID: 15363462
[TBL] [Abstract][Full Text] [Related]
25. BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma.
Villanueva H; de Cerio AL; Inoges S; Pastor F; Soldevilla MM; Bendandi M
Expert Rev Vaccines; 2011 Dec; 10(12):1661-9. PubMed ID: 22085168
[TBL] [Abstract][Full Text] [Related]
26. Cell based cancer vaccines: regulatory and commercial development.
Copier J; Ward S; Dalgleish A
Vaccine; 2007 Sep; 25 Suppl 2():B35-46. PubMed ID: 17916462
[TBL] [Abstract][Full Text] [Related]
27. Cytokine gene-mediated immunotherapy: current status and future perspectives.
Jinushi M; Tahara H
Cancer Sci; 2009 Aug; 100(8):1389-96. PubMed ID: 19459853
[TBL] [Abstract][Full Text] [Related]
28. Future of idiotypic vaccination for B-cell lymphoma.
de Cerio AL; Inogés S
Expert Rev Vaccines; 2009 Jan; 8(1):43-50. PubMed ID: 19093772
[TBL] [Abstract][Full Text] [Related]
29. Dendritic cell-based immunotherapy.
Osada T; Clay TM; Woo CY; Morse MA; Lyerly HK
Int Rev Immunol; 2006; 25(5-6):377-413. PubMed ID: 17169781
[TBL] [Abstract][Full Text] [Related]
30. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.
Inogès S; Rodrìguez-Calvillo M; Zabalegui N; Lòpez-Dìaz de Cerio A; Villanueva H; Soria E; Suárez L; Rodríguez-Caballero A; Pastor F; García-Muñóz R; Panizo C; Pèrez-Calvo J; Melero I; Rocha E; Orfao A; Bendandi M; ;
J Natl Cancer Inst; 2006 Sep; 98(18):1292-301. PubMed ID: 16985248
[TBL] [Abstract][Full Text] [Related]
31. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
32. Vaccination strategies in the treatment of lymphomas.
Veelken H; Osterroth F
Oncology; 2002; 62(3):187-200. PubMed ID: 12065865
[TBL] [Abstract][Full Text] [Related]
33. The use of idiotype as a target for clinical immunotherapy of B cell malignancies.
Kim SB; Kwak LW
Cancer Chemother Biol Response Modif; 2001; 19():289-95. PubMed ID: 11686018
[No Abstract] [Full Text] [Related]
34. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
35. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
36. Current status of therapeutic vaccines for non-Hodgkin's lymphoma.
Hurvitz SA; Timmerman JM
Curr Opin Oncol; 2005 Sep; 17(5):432-40. PubMed ID: 16093791
[TBL] [Abstract][Full Text] [Related]
37. Developments in cancer vaccination.
Lysaght J; Todryk S
Curr Opin Investig Drugs; 2003 Jun; 4(6):716-21. PubMed ID: 12901231
[TBL] [Abstract][Full Text] [Related]
38. Dendritic-cell-based therapeutic vaccination against cancer.
Nestle FO; Farkas A; Conrad C
Curr Opin Immunol; 2005 Apr; 17(2):163-9. PubMed ID: 15766676
[TBL] [Abstract][Full Text] [Related]
39. Accomplishments and perspectives of immunological interventions in lymphoproliferative disorders.
Milosević DB
J Exp Clin Cancer Res; 2004 Mar; 23(1):9-13. PubMed ID: 15149145
[TBL] [Abstract][Full Text] [Related]
40. Vaccines in lymphoma.
Levy R
Clin Adv Hematol Oncol; 2004 Jul; 2(7):424, 427. PubMed ID: 16163215
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]